Johnson & Johnson Announces Its Phase 1 Trial Of Intravesical Drug-Releasing System With Erdafitinib In Participants With Intermediate-Risk And High-Risk NonβMuscle-Invasive Bladder Cancer Meets Primary Endpoint, Shows Complete, Durable Responses In Patients
unknown
π
Published: 2026-03-13 12:39
π° Source: Benzinga
π Words: 26
π Article Content
Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with
π Summary
Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:45
Updated At:
2026-03-20 04:09:45
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A
AMP - Ameriprise Financial Inc.
Relevance: N/A